On Thursday, the House Committee on Oversight and Government Reform will question Turing Pharmaceuticals officials, including former CEO Martin Shkreli, on the company’s unconscionable price gouging on a life-saving drug.
Following Turing’s purchase of Daraprim, the price for the drug skyrocketed from $13.50 per pill to an unconscionable $750. Daraprim is a lifesaving treatment for toxoplasmosis, a parasitic infection affecting patients with compromised immune systems including those who are pregnant or living with HIV. Medical organizations have estimated that this predatory move could increase the average cost per year for an adult patient reliant on the drug to more than $630,000.
Internal Turing documents released this week by the House Oversight and Government Reform Committee lay bare the greed behind Shkreli’s decision to increase by 5,000 percent the cost of the life-saving drug, and revealed the company’s desire that HIV and AIDS activists would “sit this out.” Shkreli, who resigned from Turing after coming under investigation for securities fraud, is expected to invoke his Fifth Amendment right not to testify at Thursday’s hearing.
The unprecedented hike preys on the most the vulnerable individuals in our society and those least able to shoulder the additional cost burden – and Turing Pharmaceuticals banked on you not noticing.
HRC is asking its more than 1.5 million members and supporters to keep the pressure on Turing Pharmaceuticals and its current CEO Ron Tilles to roll back the price of the drug immediately and to call for real steps to be taken to ensure lifesaving medications are readily affordable and available.
To let the committee know that we’re watching, HRC is calling on our followers to tweet to the committee today and throughout the hearing tomorrow to hold Turing accountable.